

## **OCTREOTIDE**

**PRESENTATION:** 50micrograms in 1mL, 100microgram in 1mL or

500micrograms in 1mL ampoules.

**INDICATION:** Carcinoid Syndrome, reducing pancreatic

secretions, reducing pancreatic hormone secretion and other endocrine disorders

DOSE AND ADMINISTRATION:

See UKINETS bitesize guidance If unsure

always consult with Endocrinology.

# Subcutaneous injection

Give undiluted.

## Bolus intravenous injection

• Dilute each mL (any strength) with 1-9mL of sodium chloride 0.9%.

## Continuous intravenous infusion

Concentration	Administration	Administration rate
	instructions	
12.5micrograms/hr	300micrograms in 250mL	10mL/hr
	of sodium chloride 0.9%	
25micrograms/hr	600micrograms in 250mL	10mL/hr
	of sodium chloride 0.9%	
50micrograms/hr	1200micrograms in 250mL	10mL/hr
-	of sodium chloride 0.9%	


**STABILITY:** Physically and chemically stable for 24 hours.

Note: Sun Pharmaceutical Octreotide product

expiry reduces to 8 hours at 25°C.

Critical Care Guidelines: OCTREOTIDE		
Authors: Erin Fraser, Dr A Hurry		
Document Version: 1	Authoriser: Lothian Critical Care Directorate QIT Editorial Board	
Authorisation Date: January 2024	Review Date: January 2026	





## **UKINETS** bitesize guidance

Critical Care Guidelines: OCTREOTIDE	
Authors: Erin Fraser, Dr A Hurry	
Document Version: 1	Authoriser: Lothian Critical Care Directorate QIT Editorial Board
Authorisation Date: January 2024	Review Date: January 2026

#### Critical Care Guidelines

#### FOR CRITICAL CARE USE ONLY



#### References

- 1. UKINETS Bitesize guidance on periop management of Carcinoid syndrome
- 2. Woltering EA, Wright AE, Stevens MA, et al. Development of effective prophylaxis against Intra-operative carcinoid crisis. Journal of Clinical Anesthesia 2016; 32: 189–193
- 3. Condron ME, Pommier SJ, Pommier RF. Continuous infusion of octreotide combined with perioperative octreotide bolus does not prevent intraoperative carcinoid crisis. Surgery 2016;159:358-67
- 4. Kinney MAO, Warner ME, Nagorny DM, et al. Perianaesthetic risks and outcomes of Abdominal Surgery for metastatic carcinoid tumours. British Journal of Anaesthesia 2001; 87(3):447-52
- 5. Castillo JG, Filsoufi F, Adams DH, et al. Management of patients undergoing multivalvular Surgery For carcinoid heart disease: the role of the anaesthetist. British Journal of Anaesthesia 2008; 101(5): 618-26
- 6. Injectable medicines guide Octrotide (version 9). Available from <u>Injectable Medicines</u> <u>Guide Display Octrotide Intravenous Version 9 IVGuideDisplayMain.asp</u> (medusaimg.nhs.uk) Last updated 5/9/23. Accessed 3/11/23.
- 7. Summary of Product Characteristics Octreotide 100micrograms/mL (Hospira). Available from: Octreotide 100 micrograms/1ml Solution for Injection Summary of Product Characteristics (SmPC) (emc) (medicines.org.uk) Last updated 15/06/22. Accessed 3/11/23.

Critical Care Guidelines: OCTREOTIDE	
Authors: Erin Fraser, Dr A Hurry	
Document Version: 1	Authoriser: Lothian Critical Care Directorate QIT Editorial Board
Authorisation Date: January 2024	Review Date: January 2026